Farallon Capital Management
http://www.faralloncapital.com/farallon/index.htmFarallon Capital Management is an investment firm than manages equity capital for institutions and high net worth individuals. The firm's institutional investors are primarily college endowments and foundations. Farallon primarily invests in businesses and securities that are undergoing change or will appreciate because of an expected event which includes mergers, restructurings, recapitalizations or other major changes. The firm seeks to build strong relationships with the management of companies in which it invests.
View Older Stories View More Recent Stories
-
Form SC 13G Mercury Ecommerce Acquis Filed by: Farallon Capital Partners, L.P.
-
Cell and Gene Therapy Firms Grab Over $11 Billion So Far in 2021
-
Form SC 13G Caribou Biosciences, Filed by: Farallon Capital Partners, L.P.
-
Zentera Therapeutics Announces Closing of $75 Million Series B Financing
-
Zentera Therapeutics Announces Closing of $75 Million Series B Financing
-
Form SC 13G Imago BioSciences, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form D/A Farallon Capital F5 Inve
-
Form D/A Farallon Capital F5 Inve
-
Form SC 13G Shelter Acquisition Corp Filed by: Farallon Capital Partners, L.P.
-
POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company
-
POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company
-
Senior Japanese lawmaker accuses Toshiba activists of short-termism
-
Imago BioSciences’ Bomedemstat Demonstrates Continued Encouraging Clinical Activity in Phase 2 Data for Treatment of Essential Thrombocythemia and Myelofibrosis at EHA 2021 Virtual Congress
-
Imago BioSciences Appoints Wan-Jen Hong, M.D., as Chief Medical Officer
-
CP Group, Formerly Crocker Partners, Purchases Trio Of Prominent Atlanta Suburb Office Towers In Joint Venture With Farallon Capital Management
-
GenapSys Announces $70 Million in Series D Equity Financing and Expansion of its Board of Directors
-
Form SC 13D/A Playa Hotels & Resorts Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Imago BioSciences to Present Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at 2021 European Hematology Association Virtual Congress
-
BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncology
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Dec 31
-
Form 13F-NT Farallon Capital Europe For: Mar 31
-
Form 13F-HR FARALLON CAPITAL MANAGEM For: Mar 31
-
Toshiba unit hacked by DarkSide, conglomerate to undergo strategic review
-
Form SC 13G Disruptive Acquisition Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G ARYA Sciences Acquisitio Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G Decarbonization Plus Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G Big Sky Growth Partners, Filed by: Farallon Capital Partners, L.P.
-
NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform
-
Affinia Therapeutics Closes $110 Million Series B Financing
-
Form SC 13G Khosla Ventures Acquisit Filed by: Farallon Capital Partners, L.P.
-
Exscientia Announces Investment of up to $525M
-
Toshiba must seek suitors, another big shareholder says, after CVC's $21 billion offer
-
LUMICKS Raises $93 Million in Series D Financing
-
Tango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement to Create Publicly Listed Precision Medicine Company Focused on the Next Generation of Targeted Cancer Therapies
-
Exclusive: Toshiba CEO faced board ouster before $20 billion buyout offer - sources
-
Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors
-
Toshiba CEO to step down as board meets Wednesday to consider his future: source
-
Farallon Comments on Privatization Proposal to Toshiba by CVC
-
Toshiba faces investor call to seek alternatives to CVC bid
-
Better Therapeutics to Become Publicly Traded via Merger with Mountain Crest Acquisition Corp. II (MCAD)
-
Better Therapeutics to Become Publicly Traded Prescription Digital Therapeutics Company via Merger with Mountain Crest Acquisition Corp. II
-
Form SC 13G Khosla Ventures Acquisit Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
SomaLogic to Combine with SPAC CM Life Sciences II (CMIIU)
-
SomaLogic, Leading AI-Data Driven Proteomics Platform for Advanced Research and Clinical Applications, to Combine with CM Life Sciences II, to Drive Growth and Expand Technology Platform
-
Form SC 13G Longboard Pharmaceutical Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Activist-backed proposal for Toshiba probe received 58% of shareholder votes
-
Shareholder Votes at Toshiba EGM Represent Clear Mandate for Greater Transparency and Accountability
-
Toshiba shareholders vote for probe in landmark win for Japan corporate governance
-
Ventyx Biosciences Doses First Subject in a Phase 1 Trial of VTX-958, a Selective Allosteric TYK2 Inhibitor for Autoimmune Diseases
-
Activist Toshiba shareholders tipped to win crucial vote on independent probe this week

